Similarly, within the domain of multiple myeloma (MM), a significant contingent of patients exhibited a discernible downregulation of B cell maturation antigen (BCMA) subsequent to therapeutic interventions centered on BCMA-targeting CAR-T strategies [16, 17]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.